Impact of the florida medicaid prior-authorization program on use of antipsychotics by children under age six

Psychiatric Services

Volumn 63, Issue 12, 2012, Pages 1257-1260

  Constantine, Robert ^a   Bengtson, Michael A ^b   Murphy, Tanya ^b   McPherson, Marie ^a   Andel, Ross ^b   Jones, Mary Elizabeth ^c   Donaldson Guenther, Christina ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Florida Agency for Health Care Administration   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHILD; CHILD PSYCHIATRY; CONDUCT DISORDER; DISEASE SEVERITY; DRUG USE; FEMALE; HEALTH CARE QUALITY; HUMAN; IMPULSIVENESS; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MOOD DISORDER; PRESCHOOL CHILD; UNITED STATES; INSURANCE; ORGANIZATION AND MANAGEMENT;

ANTIPSYCHOTIC AGENTS; CHILD; CHILD PSYCHIATRY; CHILD, PRESCHOOL; FEMALE; FLORIDA; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE COVERAGE; MALE; MEDICAID; UNITED STATES;

EID: 84878677753     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201100346     Document Type: Article

References (14)

1. Zito JM, Safer DJ, Valluri S, et al: Psychotherapeutic medication prevalence in Medicaid-insured preschoolers. Journal of Child and Adolescent Psychopharmacology 17:195-203, 2007
2. Patel NC, Crismon ML, Hoagwood K, et al: Trends in the use of typical and atypical antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 44:548-556, 2005
3. Olfson M, Crystal S, Huang C, et al: Trends in antipsychotic drug use by very young, privately insured children. Journal of the American Academy of Child and Adolescent Psychiatry 49:13-23, 2010
4. Gagliano A, Germanò E, Pustorino G, et al: Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. Journal of Child and Adolescent Psychopharmacology 14:39-47, 2004
5. Biederman J, Mick E, Hammerness P, et al: Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biological Psychiatry 58:589-594, 2005
6. Jensen PS, Buitelaar J, Pandina GJ, et al: Management of psychiatric disorders in children and adolescents with atypical antipsychotics: A systematic review of published clinical trials. European Child and Adolescent Psychiatry 16:104-120, 2007
7. Patel NC, Crismon ML, Hoagwood K, et al: Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. Journal of Child and Adolescent Psychopharmacology 15: 270-284, 2005
8. Coyle JT: Psychotropic drug use in very young children. JAMA 283:1059-1060, 2000
9. De Hert M, Dobbelaere M, Sheridan EM, et al: Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry 26:144-158, 2011
10. Laita P, Cifuentes A, Doll A, et al: Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. Journal of Child and Adolescent Psychopharmacology 17:487-502, 2007
11. Constantine R: The use of antipsychotic medications among children 0-5 and 6-10 years old in Florida's Medicaid program, 2010. Available at www.medicaidmentalhealth.org
12. Constantine R, Jentz S, Bengtson M, et al: Exposure to antipsychotic medications over a 4-year period among children who initiated antipsychotic treatment before their sixth birthday. Pharmacoepidemiology and Drug Safety 21:152-160, 2012
13. Liang K-Y, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika 73:13-22, 1986
14. Drug Details US. Silver Spring, Md, Food and Drug Administration, 2010. Available at www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm